Comments
Glenmark Pharmaceuticals has received final approval from the US health regulator for Amlodipine and Olmesartan Medoxomil tablets used in the treatment of hypertension.
“Glenmark Pharmaceuticals Inc., USA has been granted final approval by the United States Food & Drug Administration (USFDA) for Amlodipine and Olmesartan Medoxomil tablets, 5 mg/20 mg, 5 mg/40 mg, 10 mg/20 mg, and 10 mg/40 mg,” the company said in a BSE filing today.
The approved product is a generic version of Daiichi Sankyo’s Azor.
According to IMS Health sales data for the 12 months to May 2017, Azor tablets achieved annual sales of approximately $211.6 million, Glenmark said.
The company’s current portfolio consists of 119 products authorised for distribution in the US marketplace and 66 Abbreviated New Drug Applications (ANDA) pending approval with USFDA.
Glenmark Pharmaceuticals’ shares were trading at Rs 666 per scrip on the BSE, up 1.65 per cent.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.